BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Almonacid-Mendoza HL, Humbert MV, Dijokaite A, Cleary DW, Soo Y, Hung MC, Orr CM, Machelett MM, Tews I, Christodoulides M. Structure of the Recombinant Neisseria gonorrhoeae Adhesin Complex Protein (rNg-ACP) and Generation of Murine Antibodies with Bactericidal Activity against Gonococci. mSphere 2018;3:e00331-18. [PMID: 30305317 DOI: 10.1128/mSphere.00331-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Lim KYL, Mullally CA, Haese EC, Kibble EA, McCluskey NR, Mikucki EC, Thai VC, Stubbs KA, Sarkar-Tyson M, Kahler CM. Anti-Virulence Therapeutic Approaches for Neisseria gonorrhoeae. Antibiotics (Basel) 2021;10:103. [PMID: 33494538 DOI: 10.3390/antibiotics10020103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Baarda BI, Zielke RA, Holm AK, Sikora AE. Comprehensive Bioinformatic Assessments of the Variability of Neisseria gonorrhoeae Vaccine Candidates. mSphere 2021;6:e00977-20. [PMID: 33536323 DOI: 10.1128/mSphere.00977-20] [Reference Citation Analysis]
3 Dijokaite A, Humbert MV, Borkowski E, La Ragione RM, Christodoulides M. Establishing an invertebrate Galleria mellonella greater wax moth larval model of Neisseria gonorrhoeae infection. Virulence 2021;12:1900-20. [PMID: 34304706 DOI: 10.1080/21505594.2021.1950269] [Reference Citation Analysis]
4 Lin EY, Adamson PC, Klausner JD. Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions. Drugs 2021;81:1153-69. [PMID: 34097283 DOI: 10.1007/s40265-021-01530-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Zhu T, McClure R, Harrison OB, Genco C, Massari P. Integrated Bioinformatic Analyses and Immune Characterization of New Neisseria gonorrhoeae Vaccine Antigens Expressed during Natural Mucosal Infection. Vaccines (Basel) 2019;7:E153. [PMID: 31627489 DOI: 10.3390/vaccines7040153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol 2019;10:321. [PMID: 30873172 DOI: 10.3389/fimmu.2019.00321] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Clow F, O'Hanlon CJ, Christodoulides M, Radcliff FJ. Feasibility of Using a Luminescence-Based Method to Determine Serum Bactericidal Activity against Neisseria gonorrhoeae. Vaccines (Basel) 2019;7:E191. [PMID: 31766474 DOI: 10.3390/vaccines7040191] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Ragland SA, Gray MC, Melson EM, Kendall MM, Criss AK. Effect of Lipidation on the Localization and Activity of a Lysozyme Inhibitor in Neisseria gonorrhoeae. J Bacteriol 2020;202:e00633-19. [PMID: 32041800 DOI: 10.1128/JB.00633-19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Humbert MV, Jackson A, Orr CM, Tews I, Christodoulides M. Characterization of two putative Dichelobacter nodosus footrot vaccine antigens identifies the first lysozyme inhibitor in the genus. Sci Rep 2019;9:10055. [PMID: 31296905 DOI: 10.1038/s41598-019-46506-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]